These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31093562)

  • 41. Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study.
    Fung CS; Wan EY; Chan AK; Lam CL
    BMC Nephrol; 2017 Feb; 18(1):47. PubMed ID: 28152985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
    Vetterlein MW; Gild P; Kluth LA; Seisen T; Gierth M; Fritsche HM; Burger M; Protzel C; Hakenberg OW; von Landenberg N; Roghmann F; Noldus J; Nuhn P; Pycha A; Rink M; Chun FK; May M; Fisch M; Aziz A;
    BJU Int; 2018 Jan; 121(1):101-110. PubMed ID: 28905486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0-14 years: a population-based retrospective cohort study.
    Jansson Sigfrids F; Groop PH; Harjutsalo V
    Lancet Diabetes Endocrinol; 2022 Jul; 10(7):489-498. PubMed ID: 35489369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Competing Risks Methods Are Recommended for Estimating the Cumulative Incidence of Revision Arthroplasty for Health Care Planning Purposes.
    Lacny S; Faris P; Bohm E; Woodhouse LJ; Robertsson O; Marshall DA
    Orthopedics; 2021; 44(4):e549-e555. PubMed ID: 34292813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.
    Forsblom C; Harjutsalo V; Thorn LM; Wadén J; Tolonen N; Saraheimo M; Gordin D; Moran JL; Thomas MC; Groop PH;
    J Am Soc Nephrol; 2011 Mar; 22(3):537-44. PubMed ID: 21335512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Albuminuria independently predicts cardiovascular and all-cause mortality in a middle-aged and elderly Chinese population.
    Chen YY; Li YY; Lu YH; Dou JT; Wang SY; Lu JM
    Scand J Clin Lab Invest; 2012 Jul; 72(4):281-6. PubMed ID: 22384979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease.
    Jiang Y; Fine JP; Mottl AK
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):133-140. PubMed ID: 29580577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Association of Atrial Fibrillation and Ischemic Stroke in Patients on Hemodialysis: A Competing Risk Analysis.
    Findlay M; MacIsaac R; MacLeod MJ; Metcalfe W; Sood MM; Traynor JP; Dawson J; Mark PB
    Can J Kidney Health Dis; 2019; 6():2054358119878719. PubMed ID: 31632680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Impact of the COVID-19 epidemic in Friuli Venezia Giulia Region (Northern Italy): assessment of factors associated with the risk of death by competing risks analysis].
    Castriotta L; Rosolen V; Barbiero F; Tomietto M; de Dottori M; Barbone F; Zamaro G
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):128-135. PubMed ID: 33412803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of competing risks analysis improved prognostic assessment of patients with decompensated chronic heart failure and reduced left ventricular ejection fraction.
    Scrutinio D; Guida P; Passantino A; Ammirati E; Oliva F; Lagioia R; Frigerio M
    J Clin Epidemiol; 2018 Nov; 103():31-39. PubMed ID: 30009940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular disease, ESRD, and death: interpreting competing risk analyses.
    Grams ME; Coresh J; Segev DL; Kucirka LM; Tighiouart H; Sarnak MJ
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1606-14. PubMed ID: 22859747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation.
    Abdel-Qadir H; Fang J; Lee DS; Tu JV; Amir E; Austin PC; Anderson GM
    Circ Cardiovasc Qual Outcomes; 2018 Jul; 11(7):e004580. PubMed ID: 29997149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Competing risks analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the Scottish population.
    Rajendrakumar AL; Hapca SM; Nair ATN; Huang Y; Chourasia MK; Kwan RS; Nangia C; Siddiqui MK; Vijayaraghavan P; Matthew SZ; Leese GP; Mohan V; Pearson ER; Doney ASF; Palmer CNA
    BMC Med; 2023 Aug; 21(1):304. PubMed ID: 37563596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.
    Mozumder SI; Rutherford MJ; Lambert PC
    BMC Med Res Methodol; 2021 Mar; 21(1):52. PubMed ID: 33706711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Proportional Hazards Regression Model for the Sub-distribution with Covariates Adjusted Censoring Weight for Competing Risks Data.
    He P; Eriksson F; Scheike TH; Zhang MJ
    Scand Stat Theory Appl; 2016 Mar; 43(1):103-122. PubMed ID: 27034534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
    Åkerblom A; Clare RM; Lokhnygina Y; Wallentin L; Held C; Van de Werf F; Moliterno DJ; Patel UD; Leonardi S; Armstrong PW; Harrington RA; White HD; Aylward PE; Mahaffey KW; Tricoci P
    Am Heart J; 2016 Aug; 178():1-8. PubMed ID: 27502846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort.
    Anyanwagu U; Donnelly R; Idris I
    Am J Nephrol; 2019; 49(2):146-155. PubMed ID: 30677760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors: a population-based cohort study.
    Angriman F; Lawler PR; Shah BR; Martin CM; Scales DC;
    Crit Care; 2023 Jul; 27(1):302. PubMed ID: 37525272
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.